Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma

Laura Samples, Hossein Sadrzadeh, Matthew J. Frigault, Caron A. Jacobson, Mehdi Hamadani, Ashwath Gurumurthi, Paolo Strati, Roni Shouval, Ariela Noy, Peter A. Riedell, Saurabh Dahiya, David G. Maloney, Brian G. Till, Alexandre V. Hirayama, Jordan Gauthier, Ajay K. Gopal, Stephen D. Smith, Christina Poh, Ryan Lynch, Chaitra UjjaniMengyang Di, Vikram Raghunathan, Mehrdad Shakib-Azar, Kikkeri N. Naresh, Ted A. Gooley, Jean Yared, Michael D. Jain, Frederick L. Locke, Lori Ann Leslie, Narendranath Epperla, Monalisa Ghosh, Alan Skarbnik, Brian T. Hill, Manali K. Kamdar, Valentin Ortiz-Maldonado, Nuria Martinez-Cibrian, Leyla Shune, Mazyar Shadman

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Burkitt lymphoma (BL) is an aggressive B-cell lymphoma that is associated with poor outcomes in patients with relapsed/refractory disease. This multicenter, retrospective study evaluated real-world CD19 chimeric antigen receptor (CAR) T-cell therapy outcomes in patients with relapsed/refractory BL using data abstracted from the medical records. In total, 31 patients received CAR T cells after a median of 3 previous therapies (range, 1-6). Patients received axicabtagene ciloleucel (n = 19), lisocabtagene maraleucel (n = 4), tisagenlecleucel (n = 4), or other agents (n = 4). Grade 1 to 2 cytokine release syndrome occurred in 83.9% of patients (grade ≥3, 65%), and grade 1 to 2 immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 29% of patients (grade ≥3, 19.4%). The 28-day mortality rate was 16.1%, including 1 patient who died from grade 5 ICANS. The overall response rate at 1 month was 58.0% with a complete response (CR) rate of 41.9%; however, the 6-month CR rate was only 19.4%. The median progression-free survival was 2.3 months (95% confidence interval, 1.0-9.0), and the median overall survival was 6.0 months (95% confidence interval, 1.9-11.5). Three patients (9.7%) received consolidative allogeneic stem cell transplants, but all subsequently relapsed. In conclusion, CD19 CAR T-cell therapy infrequently delivers long-term disease control in BL. Further investigation is needed to determine the most effective alternative management strategy for these patients.

Original languageEnglish
Pages (from-to)2762-2767
Number of pages6
JournalBlood
Volume145
Issue number23
Early online date12 Feb 2025
DOIs
StatePublished - 5 Jun 2025
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2025 American Society of Hematology

Fingerprint

Dive into the research topics of 'Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma'. Together they form a unique fingerprint.

Cite this